Welcome to our dedicated page for Lifeway Food SEC filings (Ticker: LWAY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for Lifeway Foods, Inc. (NASDAQ: LWAY), an Illinois-based manufacturer of probiotic, cultured and fermented dairy foods. Through these filings, investors can review how the company reports financial performance, governance changes and key agreements that affect LWAY common stock.
Recent Form 8-K current reports document a range of material events. One 8-K dated November 12, 2025 furnishes five-year financial projections that Lifeway provided to Danone North America PBC during due diligence for a potential transaction, including net sales, gross profit, operating income, Adjusted EBITDA, capital expenditures and free cash flow. Other 8-Ks disclose estimated unaudited net sales for a fiscal quarter, the execution of a Cooperation Agreement with Danone, the appointment and resignation of directors, and the scheduling of annual shareholder meetings.
Filings also describe governance and rights arrangements. An 8-K dated October 29, 2025 outlines Amendment No. 1 to the Shareholder Rights Agreement, extending the expiration of a shareholder rights plan and explaining the board’s rationale related to concentrated share ownership and potential accumulation of control without a premium. Another 8-K filed September 30, 2025 details the Cooperation Agreement with Danone, including board refreshment, voting commitments and registration rights for Danone’s holdings.
On Stock Titan, Lifeway’s SEC filings are updated in step with the EDGAR system and paired with AI-powered summaries that explain the significance of each document in clear language. Users can quickly scan 8-K disclosures for governance and transaction developments, and refer to annual and quarterly reports when available for a broader view of Lifeway’s financial condition and risk factors, without having to interpret every technical section themselves.
Form 144 Notice of Proposed Sale filed by Lifeway Foods director Jason Scher, indicating intent to sell 16,366 shares of common stock with an aggregate market value of $396,734.75 through Morgan Stanley Smith Barney on NASDAQ.
The securities to be sold were acquired through multiple private transactions as compensation between 2021-2023:
- 3,802 shares each on 07/15/2021, 07/15/2022, and 07/15/2023
- 2,221 shares on 06/20/2021
- 2,739 shares on 06/20/2022
Recent trading activity shows Scher has already sold 8,200 shares for total proceeds of $198,604 through five separate transactions on 06/26/2025. The filing confirms no knowledge of material adverse information regarding Lifeway Foods' operations.
Lifeway Foods director Jason Scher has filed Form 144, indicating his intention to sell 8,200 shares of common stock with an aggregate market value of $198,604 through Morgan Stanley Smith Barney LLC. The planned sale is scheduled for June 26, 2025, on the NASDAQ exchange.
The shares to be sold were acquired through multiple compensation-based private acquisitions from the issuer between 2019-2021, including:
- 1,648 shares on June 15, 2019
- 1,647 shares on June 15, 2020
- 2,740 shares on June 20, 2020
- 1,647 shares on June 15, 2021
- 518 shares on June 20, 2021
The filing indicates that Scher has not sold any company securities in the past three months and affirms no knowledge of undisclosed material adverse information regarding Lifeway Foods' operations. The company currently has 15,203,241 shares outstanding.
Lifeway Foods announced a Separation Agreement with former executive Amy Feldman on June 16, 2025. The agreement includes significant compensation and equity arrangements:
- A lump sum payment of $555,313.13, subject to statutory deductions
- Immediate vesting of 7,875 restricted stock units
- Vesting of 5,448 performance stock units under the 2022 Omnibus Incentive Plan
The agreement includes a comprehensive release of claims by Feldman and confirms that no additional compensation or benefits will be provided beyond those specified. The settlement fulfills all obligations under Feldman's original executive employment agreement from October 31, 2018. This material event follows her previously reported termination announced in March 2025.